What is Serva?
Serva operates at the intersection of clean energy and advanced material science, focusing on the development of innovative nuclear technologies. By specializing in the production of radioisotopes and specialized nuclear fuels, the company addresses two distinct yet critical sectors: oncology-focused cancer treatments and sustainable power generation. Their proprietary Smart Nuclear Materials technology is designed to enhance reactor safety and operational efficiency, effectively transforming nuclear waste into a viable resource. This dual-market approach positions Serva as a unique player in the energy transition, leveraging nuclear physics to solve complex climate and healthcare challenges simultaneously.
How much funding has Serva raised?
Serva has raised a total of $2.5M across 1 funding round:
Stock/Share Issuance
$2.5M
Stock/Share Issuance (2026): $2.5M, investors not publicly disclosed
Key Investors in Serva
Undisclosed Investors
What's next for Serva?
With this major enterprise-level funding, Serva is expected to scale its manufacturing capabilities and expand its research and development pipeline. The strategic deployment of this capital will likely focus on optimizing the supply chain for radioisotopes, which are essential for modern medical diagnostics and therapeutics. Furthermore, the company is poised to advance its reactor safety initiatives, potentially setting new industry standards for sustainable nuclear energy. As Serva moves into this next phase of growth, the focus will remain on commercializing its material science breakthroughs and solidifying its role as a key infrastructure provider in the global clean energy ecosystem.
See full Serva company page
